Results 251 to 260 of about 116,104 (295)
Clinical Pharmacology &Therapeutics, EarlyView.Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović +11 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Interferon-Gamma Release Assays
Clinics in Laboratory Medicine, 2014Diagnosis of latent tuberculosis infection (LTBI) should be targeted toward individuals and groups with high risk of progression to active tuberculosis (TB). Low-risk populations should not be screened. Interferon-gamma release assays (IGRAs) perform as well or better than the tuberculin skin test in most targeted populations.
Robert, Belknap, Charles L, Daley
openaire +2 more sources
Interferon gamma release assays: principles and practice
Enfermedades Infecciosas y Microbiología Clínica, 2010The last decade has witnessed significant advances in mycobacterial genomics and cellular research which have resulted in the development of two new blood tests, the enzyme-linked immunospot assay (ELISpot) (TSPOT.TB, Oxford Immunotec, Oxford, UK) and the enzyme-linked immunosorbent assay (ELISA) (QuantiFERON-TB Gold In-Tube, Cellestis, Carnegie ...
Ajit, Lalvani, Manish, Pareek
openaire +2 more sources
Tuberculin skin test versus interferon-gamma release assays
Acta Clinica Belgica, 2014Dear Editor,We would like to discuss on the publication on ‘Tuberculin skin test versus interferon-gamma release assays.’1 De Keyser et al.
S S, Tin, V, Wiwanitkit
openaire +2 more sources
Role of interferon-gamma release assays in healthcare workers
Journal of Hospital Infection, 2009The advent of interferon-gamma release assays (IGRAs) provides new options for detection of latent tuberculosis infection (LTBI). This is particularly relevant to healthcare workers (HCWs), who are at higher risk of infection, but who have often also been vaccinated.
J E, Swindells +3 more
openaire +2 more sources
Interferon-gamma release assays and TB diagnosis
Drug and Therapeutics Bulletin, 2009Worldwide in 2007, there were an estimated 9.27 million new cases of active tuberculosis (TB) and 1.8 million deaths related to the disease. However, in most people with TB, the infection is 'latent'; the underlying cause, Mycobacterium tuberculosis, remains alive but patients are asymptomatic and non-infectious.
openaire +2 more sources
Interferon-gamma release assays for tuberculosis: current and future applications
Expert Review of Respiratory Medicine, 2013Interferon-gamma release assays (IGRAs) represent the first new tool to diagnose latent tuberculosis infection for more than 100 years. They have advantages over the traditional tuberculin skin test which has a poor specificity due to false-positive responses in people who are BCG vaccinated as there is a cross-reactivity of proteins present in both ...
Muhunthan, Thillai +3 more
openaire +2 more sources
Interferon gamma release assays for diagnosing active and latent tuberculosis
Expert Opinion on Medical Diagnostics, 2009In view of the continuing global epidemic of tuberculosis (TB), adequate diagnosis is crucial for controlling this disease. Two commercial interferon gamma release assays (IGRA) have become available: the QuantiFERON-TB (QFT) and the T-SPOT.TB (TSPOT). They offer an important new tool for detecting both latent and active TB.
Steven Ft, Thijsen, Ailko Wj, Bossink
openaire +2 more sources